Protocol Ledger

NCT06196203 · Phase II · RECRUITING

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Interventional Phase II clinical trial protocol NCT06196203 sponsored by Akeso in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-02-07 Enrollment: 90 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06196203
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06196203
Protocol FieldVerified Registry Value
NCT IdentifierNCT06196203
Consolidated Lead SponsorAkeso
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment90 participants (ESTIMATED)
Registered Start Date2024-02-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI